ALLO supply chain intelligence for Allogene Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PFE | Pfizer Inc. | 92% | In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets and assumed certain liabilities from Pfizer |
| PFE | Pfizer Inc. | 92% | Reciprocal relationship from PFE graph: Reciprocal relationship from ALLO graph: In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to… |
| GOLDMAN-SACHS-CO-LLC | GOLDMAN-SACHS-CO-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| JEFFERIES-LLC | JEFFERIES-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| SERVIER | SERVIER | 90% | the Company acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis S.A. (Cellectis) and Servier |
| TD-SECURITIES-U-S-A-LLC | TD-SECURITIES-U-S-A-LLC | 90% | In connection with the Company’s proposed public offering, the Company has suspended the offering of any shares of its common stock pursuant to the sales agreement prospectus, dated April 25, 2024, c… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 90% | On April 14, 2026, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (col… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purpos… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC g… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from INAB graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from INAB g… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LEGN g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| OVERLAND-THERAPEUTICS-INC | OVERLAND-THERAPEUTICS-INC | 90% | Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| OVERLAND-THERAPEUTICS-SH-CO-LTD | OVERLAND-THERAPEUTICS-SH-CO-LTD | 90% | Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c… |
| FATE | Fate Therapeutics, Inc. | 72% | Reciprocal relationship from FATE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK m… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n… |
| INAB | IN8bio, Inc. | 72% | Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| TCRX | TScan Therapeutics, Inc. | 72% | Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from TCRX g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ALLO-DEBT | Debt stack $81.1M | 90% | Market cache reports total debt of $81.1M. |
| ALLO-DEBT-7684 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO-OWNER-PFIZER-INC | Pfizer Inc | 90% | 13F overlay lists Pfizer Inc as top holder; 208 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['receiving'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 |